November Recap: Psychedelic Drug Stocks Index Driven Higher By Incannex

The 5 constituents in the Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months but jumped 30% in November, likely a one-time response to a big change at Incannex.

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index had declined 46.5% over the past 3 months only to jump up 30.2% in November thanks in large part to Icannex Healthcare which, with the completion of its re-domiciliation to the U.S. on the last day of November. Below is how their performances ranked, in descending order, in November.

  1. Incannex Healthcare (IXHL): UP 423.0%
  2. Mind Medicine (MNMD): UP 33.6%
  3. Compass Pathways (CMPS): UP 13.0%
  4. Atai Life Sciences (ATAI): DOWN 1.9%
  5. GH Research (GHRS): DOWN 9.7%


Summary

The munKNEE Psychedelic Drug Stocks Index was DOWN 14.3% in August, DOWN another 14.2% in September and DOWN 27.3% in October but was UP 30.2% in November. Were IXHL excluded from the November calculation the Index would only have gone UP 5.3%, but UP never the less. The Index is now only DOWN 12.5% YTD.


More By This Author:

November Recap: 7 Largest American Cannabis MSOs Jumped 40%, On Average
November Recap: 5 Largest Canadian Cannabis Stocks Up 14%, On Average
All About Cybersecurity Stock CrowdStrike And Its Competition

Disclosure:

None

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample here).

Comments